Cagatay Ermis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cagatay Ermis has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Sreeparna Banerjee
Middle East Technical University
2 shared publications - Akin Akdag
Department of Chemistry Middle East Technical University Ankara Turkey
1 shared publication Aliye Ezgi Güleç Taşkıran
Department of Biological Sciences, Orta Doğu Teknik Üniversitesi, Ankara, Türkiye; Department of Molecular Biology and Genetics, Başkent University, Ankara, Türkiye
1 shared publication- Burak Baykara
Child and Adolescent Psychiatry Department, Medical School Dokuz Eylul University İzmir Turkey
1 shared publication - Burçin Şeyda Buran
Balıkesir Ataturk City Hospital, Turkey
1 shared publication Cemil Can Eylem
Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkiye
1 shared publication
Latest Publications
- Open Access
- 7 August 2024
- Published by Elsevier in Translational Oncology
- Vol. 48, 102078
Glutamine withdrawal leads to the preferential activation of lipid metabolism in metastatic colorectal cancer
- 7 August 2024
- Published by Elsevier in Translational Oncology
- Vol. 48, 102078
Open AccessGlutamine withdrawal leads to the preferential activation of lipid metabolism in metastatic colorectal cancer
- Open Access
- 4 March 2024
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 34 (2) , 109-118
Safety of Atypical Antipsychotics in a Child and Adolescent İnpatient Setting: A Naturalistic Study
This study’s objective was to investigate the adverse effects of atypical antipsychotics (AAPs) on the metabolic, hematological, and endocrinological systems in the inpatient environment for children and adolescents with diverse psychiatric disorders. A retrospective assessment of 208 children’s and adolescents’ medical records was conducted. All patients were on AAP monotherapy. At baseline and after treatment, measurements of body weight, height, body mass index (BMI), BMI z-score, fasting blood glucose (FBG), total cholesterol, low-density lipoprotein cholesterol, triglycerides, high-density lipoprotein cholesterol, complete blood count, liver functions, thyroid functions, and prolactin levels were made. Scores from the Children’s Global Assessment Scale (CGAS) and the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) were preserved. The overall patient population had a mean age of 14.50 ± 2.32 years, 139 girls, and 69 boys. Of the patients, 63 (30.29%) were on risperidone (RIS), 69(33.17%) were on aripiprazole (ARI), 32 (15.39%) were on quetiapine (QUE), 42 (20.19%) were on olanzapine (OLA), and 2 (0.96%) were on clozapine (CLO). In the OLA group, the BMI and BMI z-score increased more than in the RIS, QUE, and ARI groups (P = .030, P = .014, and P = .001, respectively) (P = .001). The mean difference in CGAS and HoNOSCA between the start of antipsychotic medication and hospital discharge was statistically different for all four groups (P = .001 for all). The mean FBG levels in the OLA group increased statistically significantly (P = .013, P = .021) in contrast to the RIS group. In addition, a statistically significant difference in triglycerides across the groups was found (P = .003). According to the findings of our study, children and adolescents appear to be at a significant risk for psychotropic-induced PRL increase, weight gain, metabolic, and hematological consequences. To prevent serious health problems, a meticulous risk–benefit assessment for AAPs treatment should be done between clinicians and patients and their families.
- 4 March 2024
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 34 (2) , 109-118
Open AccessSafety of Atypical Antipsychotics in a Child and Adolescent İnpatient Setting: A Naturalistic Study
This study’s objective was to investigate the adverse effects of atypical antipsychotics (AAPs) on the metabolic, hematological, and endocrinological systems in the inpatient environment for children and adolescents with diverse psychiatric disorders. A retrospective assessment of 208 children’s and adolescents’ medical records was conducted. All patients were on AAP monotherapy. At baseline and after treatment, measurements of body weight, height, body mass index (BMI), BMI z-score, fasting blood glucose (FBG), total cholesterol, low-density lipoprotein cholesterol, triglycerides, high-density lipoprotein cholesterol, complete blood count, liver functions, thyroid functions, and prolactin levels were made. Scores from the Children’s Global Assessment Scale (CGAS) and the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) were preserved. The overall patient population had a mean age of 14.50 ± 2.32 years, 139 girls, and 69 boys. Of the patients, 63 (30.29%) were on risperidone (RIS), 69(33.17%) were on aripiprazole (ARI), 32 (15.39%) were on quetiapine (QUE), 42 (20.19%) were on olanzapine (OLA), and 2 (0.96%) were on clozapine (CLO). In the OLA group, the BMI and BMI z-score increased more than in the RIS, QUE, and ARI groups (P = .030, P = .014, and P = .001, respectively) (P = .001). The mean difference in CGAS and HoNOSCA between the start of antipsychotic medication and hospital discharge was statistically different for all four groups (P = .001 for all). The mean FBG levels in the OLA group increased statistically significantly (P = .013, P = .021) in contrast to the RIS group. In addition, a statistically significant difference in triglycerides across the groups was found (P = .003). According to the findings of our study, children and adolescents appear to be at a significant risk for psychotropic-induced PRL increase, weight gain, metabolic, and hematological consequences. To prevent serious health problems, a meticulous risk–benefit assessment for AAPs treatment should be done between clinicians and patients and their families.
- Open Access
- 14 April 2022
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 4 (5) , 3448-3461
Boron Cage Triggered Micellization of a Neutral–Cationic Block Copolymer and Preparation of Boron-Containing Layer-by-Layer Microparticles
- 14 April 2022
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 4 (5) , 3448-3461
Open AccessBoron Cage Triggered Micellization of a Neutral–Cationic Block Copolymer and Preparation of Boron-Containing Layer-by-Layer Microparticles